Can Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s Tomorrow be Different? The Stock Had Increase in Shorts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

Investors sentiment decreased to 1.07 in Q2 2019. Its down 0.56, from 1.63 in 2019Q1. It dropped, as 26 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 21 funds opened positions while 58 raised stakes. 55.14 million shares or 1.40% less from 55.93 million shares in 2019Q1 were reported.
8,050 were reported by United Automobile Association. Citadel Ltd Limited Liability Company has invested 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Credit Suisse Ag owns 47,844 shares. Charles Schwab Investment Management stated it has 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Rock Springs Mngmt Ltd Partnership owns 170,500 shares or 0.31% of their US portfolio. State Of Alaska Department Of Revenue has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). 29,900 were reported by Capital Int Sarl. Moreover, Ubs Asset Mngmt Americas Incorporated has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 383,748 shares. Sg Americas Ltd holds 4,022 shares or 0% of its portfolio. 479,750 are held by Westfield Cap Lp. Sector Gamma As stated it has 0.83% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). State Of Wisconsin Investment Board has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Bancorp Of America De stated it has 79,208 shares. Utah Retirement stated it has 0.01% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Spark Inv Management Ltd, New York-based fund reported 94,500 shares.

The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) registered an increase of 5.41% in short interest. AGIO’s total short interest was 9.09M shares in September as published by FINRA. Its up 5.41% from 8.62 million shares, reported previously. With 555,300 shares average volume, it will take short sellers 16 days to cover their AGIO’s short positions.

The stock increased 6.52% or $2.32 during the last trading session, reaching $37.9. About 761,749 shares traded or 33.88% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has declined 43.99% since September 12, 2018 and is downtrending. It has underperformed by 43.99% the S&P500.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $2.37 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Globenewswire.com which released: “Agios Reports Business Highlights and First Quarter 2019 Financial Results – GlobeNewswire” on May 02, 2019, also Finance.Yahoo.com with their article: “Alibaba, Cisco, Agios Pharmaceuticals and More: Why These Stocks Are in the Spotlight – Yahoo Finance” published on May 15, 2019, Nasdaq.com published: “Agios’ (AGIO) Loss Widens in Q2, Tibsovo Drives Sales – Nasdaq” on August 01, 2019. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Nasdaq.com and their article: “Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock – Nasdaq” published on February 15, 2019 as well as Globenewswire.com‘s news article titled: “Agios Announces New Commercial Leadership Structure Nasdaq:AGIO – GlobeNewswire” with publication date: April 02, 2019.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.